0002019875-26-000003.txt : 20261104
0002019875-26-000003.hdr.sgml : 20261104
20261104172000
ACCESSION NUMBER: 0002019875-26-000003
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering
FILED AS OF DATE: 20261104
DATE AS OF CHANGE: 20261104
EFFECTIVENESS DATE: 20261104
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: AI3 Bio, Inc.
CENTRAL INDEX KEY: 0002019875
ORGANIZATION NAME:
EIN: 843148800
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-603654
FILM NUMBER: 261523786
BUSINESS ADDRESS:
STREET 1: 99 COOLIDGE AVE, SUITE 201
CITY: WATERTOWN
STATE: MA
BUSINESS PHONE: 617-701-7014
MAIL ADDRESS:
STREET 1: 99 COOLIDGE AVE, SUITE 201
CITY: WATERTOWN
STATE: MA
FORMER COMPANY:
FORMER CONFORMED NAME: Corner Therapeutics, Inc.
DATE OF NAME CHANGE: 20240415
D
1
primary_doc.xml
X0708
D
LIVE
0002019875
AI3 Bio, Inc.
99 Coolidge Ave, Suite 201
Watertown
MA
MASSACHUSETTS
02472
617-701-7014
DELAWARE
Corner Therapeutics, Inc.
Corporation
true
Steven
Altschuler
99 Coolidge Ave, Suite 201
Watertown
MA
MASSACHUSETTS
02472
Executive Officer
Director
Michael
Lyman
99 Coolidge Ave, Suite 201
Watertown
MA
MASSACHUSETTS
02472
Executive Officer
Nick
Seaver
99 Coolidge Ave, Suite 201
Watertown
MA
MASSACHUSETTS
02472
Executive Officer
Director
Fabian
Tenenbaum
99 Coolidge Ave, Suite 201
Watertown
MA
MASSACHUSETTS
02472
Director
Jeanne
Cunicelli
99 Coolidge Ave, Suite 201
Watertown
MA
MASSACHUSETTS
02472
Director
Alan
Ezekowitz
99 Coolidge Ave, Suite 201
Watertown
MA
MASSACHUSETTS
02472
Director
Jonathan
Kagan
99 Coolidge Ave, Suite 201
Watertown
MA
MASSACHUSETTS
02472
Executive Officer
Biotechnology
Decline to Disclose
- 06b
false
2026-06-09
false
true
true
The offering consists solely of an equity financing consummated following the completion of a merger transaction. The securities included in this Form D were not issued in the merger.
0
48339490
48339490
0
false
8
0
0
0
false
AI3 Bio, Inc.
/s/ Steven Altschuler
Steven Altschuler
Chief Executive Officer
2026-11-04